BUZZ-Jiangsu Hengrui Pharmaceuticals rises as Merck signs licensing deal up to $2 billion

Reuters2025-03-26
BUZZ-Jiangsu Hengrui Pharmaceuticals rises as Merck signs licensing deal up to $2 billion

** Shares of Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals 600276.SS rise 4.6% to 46.94 yuan, their biggest intraday pct gain since November 20, 2024

** Stock hits its highest level since March 20, and set for a second session of gains, if current trend holds

** Merck MRK.N has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with China-based firms

** The blue-chip CSI 300 Index .CSI300 slips 0.1% while the Shanghai Composite Index .SSEC adds 0.1%

** Shares of Shanghai-listed Jiangsu Hengrui up 0.7%, YTD

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment